Sanofi Pasteur

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

Kala Pharmaceuticals appoints Pfefer as president and CEO

Tuesday, July 17, 2012 08:09 AM

Kala Pharmaceuticals, a Waltham, Mass.-based developer of products that rapidly penetrate the mucosal barrier to treat a wide range of debilitating diseases, has appointed Guillaume Pfefer, PhD, as president, CEO and member of the board of directors.

More... »

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

Friday, May 4, 2012 08:00 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Sanofi Pasteur’s, standalone Inactivated Poliovirus Vaccine (IPV) against acute flaccid poliomyelitis (Imovax Polio). Imovax Polio will be added to the country's public immunization program on September 1.

More... »

FDA approves Sklice lotion for head lice

Friday, February 10, 2012 12:01 PM

The FDA has approved Sklice (ivermectin) lotion 0.5% for the topical treatment of head lice in patients 6 months of age and older, according to Sanofi.

More... »

Site group continues expansion toward East Coast

Monday, November 21, 2011 08:00 AM

The Pheonix, Ariz.-based site group Clinical Research Advantage (CRA) is expanding. 

More... »

CureVac, Sanofi Pasteur collaborate in $33 million research project

Tuesday, November 15, 2011 11:20 AM

CureVac has signed several agreements with Sanofi Pasteur, the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive technology platform to the development of vaccines against several infectious diseases.

More... »

Benchmark, poised for growth, adds two vice presidents

Monday, November 14, 2011 08:00 AM

Benchmark Research, an Austin, Texas-based group of six investigative sites, is making some strategic hires as it positions itself for growth.

More... »

Quintiles’ Chasse, Sanofi Pasteur’s Milam make unprecedented industry move to the site world

Monday, May 23, 2011 08:44 AM

Christine Pierre, president of the investigator site group and consultancy RxTrials, shocked parts of the industry this month when she hired Adam Chasse away from global CRO Quintiles and Dan Milam from Sanofi Pasteur, the largest company in the world devoted to vaccines.

More... »

Trial Results: Immunology/Infectious Disease

Tuesday, October 7, 2008 11:02 AM

Crucell and Sanofi Pasteur reported positive preliminary results from a phase II trial of CL-184, a vaccine for the treatment of rabies. This randomized, single-blind, controlled study enrolled 140 healthy subjects in the United States. The subjects received CL-184, a currently marketed human rabies immune globulin (HRIG) or placebo plus rabies vaccine.

More... »